Andrew Reardon, CLO & Secretary at LIGAND PHARMACEUTICALS INC (LGND), sold 5,000 shares at $223.95 ($1.1M) on 2026-06-01, disclosed to the SEC on 2026-06-02.
Scheduled sale ($1.1M) by CLO & Secretary under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $223.95 | 491 | $110K | 9.7% |
| 2 | $225.20 | 677 | $152K | 13.4% |
| 3 | $225.97 | 1,432 | $324K | 28.5% |
| 4 | $226.78 | 400 | $91K | 8.0% |
| 5 | $228.57 | 584 | $133K | 11.8% |
| 6 | $229.47 | 1,216 |
| $279K |
| 24.6% |
| 7 | $230.41 | 200 | $46K | 4.1% |
| Total | $227.06 avg | 5,000 | $1.1M | 100% |
| Filing → |
| LGND | SELL | 2026-08-04 | $1.4M | — | Filing → |
| LGND | SELL | 2026-07-06 | $1.6M | — | Filing → |
| LGND | SELL | 2026-05-04 | $1.2M | — | Filing → |